MARKET INSIGHTS

ZTOX Insights

AI-assisted articles on quarterly results, exchange filings, and earnings calls — tied to the companies you follow.

7 articles published

SUVEN
SUVEN
1 min read
Market Updates Corporate announcement

Suven Life Sciences (SUVEN): General Updates

General Updates Suven Life Sciences Limited has informed the Exchange rectification order for assesment year 2020-21 Suven Life Sciences Limited has informed the Exchange rectification order for assesment year 2020-21

Read article
SUVEN
SUVEN
1 min read
Market Updates Corporate announcement

Suven Life Sciences (SUVEN): General Updates

General Updates Suven Life Sciences Limited has informed the Exchange rectification order for assesment year 2020-21 Suven Life Sciences Limited has informed the Exchange rectification order for assesment year 2020-21

Read article
SUVEN
SUVEN
1 min read
Market Updates Corporate announcement

Suven Life Sciences (SUVEN): Company Update

Company Update Rectification order for Assesment year 2020-21 Rectification order for Assesment year 2020-21

Read article
SUVEN
SUVEN
1 min read
Market Updates Corporate announcement

Suven Life Sciences (SUVEN): Company Update

Company Update Rectification order for Assesment year 2020-21 Rectification order for Assesment year 2020-21

Read article
SUVEN
SUVEN
1 min read
Market Updates Chartink scans

Suven Life Sciences (SUVEN): 🚀 Volume Explosion: SUVEN Breaks 60-Day Average!

💹 Change: ▼ -2.34% 💰 Price: ₹268.90 📊 Volume: 2.41M 🔍 What's happening? Unusual trading activity detected! This could signal a potential breakout or significant news impact. 💡 Pro Tip: Always conduct thorough research before making investment decisions.

Read article
SUVEN
SUVEN
1 min read
Market Updates Chartink scans

SUVEN Stock at ₹273.40 with Unusual Volume Activity — ZTOX Daily Scan

Suven Life Sciences (SUVEN) stock fell 0.71% to ₹273.40 with 2.22 million shares traded, signaling unusual trading activity on Tuesday.

Read article
SUVEN
SUVEN
1 min read
Market Updates NSE filings

Suven Life Sciences DSMB Review: Phase 3 Masupirdine Study Advances

Suven Life Sciences (NSE: SUVEN) announced positive findings from a DSMB safety review and interim analysis of its ongoing global Phase 3 study of Masupirdine for Alzheimer's Disease Agitation.

Read article

Track Indian stocks with ZTOX AI

Get started free

Track Indian stocks with ZTOX AI

NSE & BSE filings, earnings, insider trades, and smart volume alerts — on WhatsApp or Telegram. No separate app to install.

Insider Deals Alert
Volume Breakouts
Block Deal Notifications
Preferential Issue Alerts
Free ₹0
Basic ₹89/mo
Advanced ₹119/mo
No credit card required to start on the free plan.
Start Free Now